ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,187.70
0.13%
Dow Jones
38,884.26
0.08%
US Dollar vs MXN
16.9226
0.09%
Brent Oil
82.785
-0.10%
Bitcoin
62,747.57
0.66%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Impel Pharmaceuticals Inc (IMPL)

  7. Impel Pharmaceuticals Inc (IMPL) Noticias

IMPL

Impel Pharmaceuticals (IMPL)

Impel Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:IMPL
FechaHoraFuenteTítuloSímboloCompañía
09/04/202415:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMPLImpel Pharmaceuticals Inc
15/02/202423:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IMPLImpel Pharmaceuticals Inc
14/02/202416:21Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:IMPLImpel Pharmaceuticals Inc
14/02/202416:16Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:IMPLImpel Pharmaceuticals Inc
14/02/202416:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMPLImpel Pharmaceuticals Inc
26/12/202315:32Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMPLImpel Pharmaceuticals Inc
05/10/202316:19Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMPLImpel Pharmaceuticals Inc
05/10/202307:00GlobeNewswire Inc.Impel Pharmaceuticals Announces Exploration of Strategic AlternativesNASDAQ:IMPLImpel Pharmaceuticals Inc
18/08/202308:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMPLImpel Pharmaceuticals Inc
15/08/202315:29Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:IMPLImpel Pharmaceuticals Inc
05/07/202309:05AllPennyStocks.comBiotech Catches Major Premarket BidNASDAQ:IMPLImpel Pharmaceuticals Inc
21/06/202305:00Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:IMPLImpel Pharmaceuticals Inc
15/06/202307:00GlobeNewswire Inc.Impel Pharmaceuticals to Present New Real-World Data for Trudhesa® at the 65th Annual Scientific Meeting of the American Headache SocietyNASDAQ:IMPLImpel Pharmaceuticals Inc
12/05/202315:23Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:IMPLImpel Pharmaceuticals Inc
12/05/202310:23Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:IMPLImpel Pharmaceuticals Inc
12/05/202307:00GlobeNewswire Inc.Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:IMPLImpel Pharmaceuticals Inc
10/05/202307:11Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:IMPLImpel Pharmaceuticals Inc
10/05/202307:00GlobeNewswire Inc.Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial OfficerNASDAQ:IMPLImpel Pharmaceuticals Inc
05/05/202307:00GlobeNewswire Inc.Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023NASDAQ:IMPLImpel Pharmaceuticals Inc
27/04/202315:10Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:IMPLImpel Pharmaceuticals Inc
27/04/202315:09Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:IMPLImpel Pharmaceuticals Inc
26/04/202307:00GlobeNewswire Inc.Impel Pharmaceuticals Presents New Data at AAN 2023 Suggesting Trudhesa® Nasal Spray is Safe to Use When Co-Administered With Commonly Prescribed Migraine MedicationsNASDAQ:IMPLImpel Pharmaceuticals Inc
14/04/202315:12Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:IMPLImpel Pharmaceuticals Inc
12/04/202315:01GlobeNewswire Inc.Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of DirectorsNASDAQ:IMPLImpel Pharmaceuticals Inc
11/04/202307:00GlobeNewswire Inc.Impel Pharmaceuticals to Present Data on Trudhesa® Nasal Spray for Treatment of Acute Migraine at 2023 American Academy of Neurology Annual MeetingNASDAQ:IMPLImpel Pharmaceuticals Inc
31/03/202315:32Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:IMPLImpel Pharmaceuticals Inc
24/03/202307:17GlobeNewswire Inc.Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateNASDAQ:IMPLImpel Pharmaceuticals Inc
17/03/202307:00GlobeNewswire Inc.Impel Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 24, 2023NASDAQ:IMPLImpel Pharmaceuticals Inc
03/03/202315:01GlobeNewswire Inc.Impel Pharmaceuticals to Participate in Upcoming Investor Conferences in MarchNASDAQ:IMPLImpel Pharmaceuticals Inc
22/02/202315:30GlobeNewswire Inc.Impel Pharmaceuticals Announces Strategic Repriortization, Continues Focus on Maximizing Trudhesa® Commercial OpportunityNASDAQ:IMPLImpel Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:IMPL

Su Consulta Reciente

NASDAQ
GOOGL
Alphabet
CCOM
US30
US 30
NYSE
CVX
Chevron
NASDAQ
TSLA
Tesla
CCOM
OILBRENT
Brent Oil
NYSE
MRK
Merck
NYSE
BAC
Bank of America
AMEX
XLE
Energy Select Sector SPDR
USI
USTECH100
US Tech 100
CCOM
US500
US 500
AMEX
XLF
Financial Select Sector
NYSE
NKE
Nike
COIN
BTCUSD
Bitcoin
COIN
SOLUSD
Solana
CCOM
SILVER
SILVER
NYSE
KO
Coca Cola
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados